According to Clinical Laboratory News, there were more than 400,000 hs-CRP tests performed in the United States last year to aid in the diagnosis of CVD1. Due to the increased volume of testing and the recent surge in research focusing on CVD risk and hs-CRP, the American Heart Association and the Centers for Disease Control released a set of guidelines in the January 2003 edition of Circulation (2003; 107:499-511). These recent guidelines named hs-CRP as the only inflammatory marker that can be recommended for use as an independent CVD risk factor. The guidelines also stated the recommended cut-off points for determining a person’s risk of developing CVD2:

<1 mg/l = Low Risk
1 –3 mg/l = Average Risk
>3 mg/l = High Risk

The ALPCO hs-CRP EIA (30-9710s) which is standardized to the CRM 470 reference material, offers a functional sensitivity of 0.124 ng/ml and a 2 hour and 15 minute incubation time. Click here to learn more about this assay, or call 1-800-592-5726.

1 Auxter S. Taking the Next Step in Primary CVD Prevention. Clinical Laboratory News. 2003:29;1.

2 Pearson TA, Mensah GA, Alexander RW, et. al. AHA/CDC Scientific Statement on Markers of Inflammatoin and Cardiovascular Disease. Circulation. 2003;107:499-511.